Connect Biopharma reported second quarter 2026 revenue of $2.8 million and a net loss per share of $0.27, outperforming consensus estimates. Results were primarily driven by milestone achievements under the Simcere partnership, while the company successfully met enrollment targets for its lead clinical programs.
Key Highlights
- Generated $2.8 million in collaboration revenue from a regulatory milestone achievement, significantly exceeding the zero-revenue forecast.
- Completed enrollment for Phase 2 Seabreeze STAT studies in asthma and COPD, with topline results expected in September 2026.
- Maintained a cash and short-term investment balance of $31.5 million, which management expects will fund operations for at least one year.